Hepatitis C – the next hurdle
This article was originally published in Scrip
Executive Summary
Every now and again the pharmaceutical/biotech industries do something remarkable. The latest clinical data for the second wave of direct-acting antivirals against the hepatitis C virus that came out of the European Association for the Study of the Liver (EASL) meeting in London last week are just that: cure rates approaching 100% are being achieved with combinations of just two oral products.